Delivery Order SPE2DB22D3102-SPE2DB25FL2UU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30-count). This competitively awarded, firm fixed price delivery order carries a ceiling value of $3,758.67 and is scheduled for completion by September 3, 2025. The contract represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (unit dose, 30 count) with a contract value of $3,124.61. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-12.5 mg tablets (30-unit dose) valued at $4,139.85. This competitive, firm fixed-price contract was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, PA, where AmerisourceBergen maintains its corporate headquarters. No set-aside designation was applied to this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,044.82 to supply Micardis HCT 80-25 mg tablet unit dose packages (30 count) with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $5,163.02 to AmerisourceBergen Drug Corp for the supply of MICARDIS HCT 40-12.5 mg tablets in unit dose packaging (30 count) on September 2, 2025, with completion expected by September 3, 2025. This contract was awarded on a non-competitive, firm fixed-price basis and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Micardis HCT 40-12.5 mg tablet unit dose packages (30 count). This competitive award, valued at $4,145.28 with firm fixed pricing, is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract contains no set-aside designation and represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a $1,108.80 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30 count). This competitively awarded, firm fixed-price contract has an ultimate completion date of August 29, 2025, with performance conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition in the federal...
- This delivery order, awarded on August 28, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $1,742.70 under firm fixed price terms. The contract is non-set-aside and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,503.31 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30-count) on August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August...
- This delivery order, awarded on August 27, 2025, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) with a ceiling value of $9,314.20. The contract utilizes firm fixed pricing with an ultimate completion date of August 28, 2025, and was competitively awarded by the Defense Logistics Agency without any set-aside designation. This delivery order...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB25FL2UUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $2,508.25. This competitive, non-set-aside award utilizes firm fixed price pricing and carries an ultimate completion date of September 4, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026, which serves as the primary pharmaceutical supply vehicle for military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order as part of its extensive federal medical procurement portfolio with the Defense Logistics Agency. The company supplies comprehensive pharmaceutical products and medical supplies to support defense medical supply chain requirements, including brand-name and generic medications across multiple therapeutic domains. This delivery order exemplifies the company's role as a critical vendor for federal military and veteran healthcare procurement needs through the DLA's competitive pharmaceutical distribution program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 9/3/25 |